NANOG Attenuates Hair Follicle-Derived Mesenchymal Stem Cell Senescence by Upregulating PBX1 and Activating AKT Signaling
Stem cells derived from elderly donors or harvested by repeated subculture exhibit a marked decrease in proliferative capacity and multipotency, which not only compromises their therapeutic potential but also raises safety concerns for regenerative medicine. NANOG—a well-known core transcription factor—plays an important role in maintaining the self-renewal and pluripotency of stem cells. Unfortunately, the mechanism that NANOG delays mesenchymal stem cell (MSC) senescence is not well-known until now. In our study, we showed that both ectopic NANOG expression and PBX1 overexpression (i) significantly upregulated phosphorylated AKT (p-AKT) and PARP1; (ii) promoted cell proliferation, cell cycle progression, and osteogenesis; (iii) reduced the number of senescence-associated-β-galactosidase- (SA-β-gal-) positive cells; and (iv) downregulated the expression of p16, p53, and p21. Western blotting and dual-luciferase activity assays showed that ectopic NANOG expression significantly upregulated PBX1 expression and increased PBX1 promoter activity. In contrast, PBX1 knockdown by RNA interference in hair follicle- (HF-) derived MSCs that were ectopically expressing NANOG resulted in the significant downregulation of p-AKT and the upregulation of p16 and p21. Moreover, blocking AKT with the PI3K/AKT inhibitor LY294002 or knocking down AKT via RNA interference significantly decreased PBX1 expression, while increasing p16 and p21 expression and the number of SA-β-gal-positive cells. In conclusion, our findings show that NANOG delays HF-MSC senescence by upregulating PBX1 and activating AKT signaling and that a feedback loop likely exists between PBX1 and AKT signaling.
Top-30
Journals
|
1
2
3
4
|
|
|
Frontiers in Cell and Developmental Biology
4 publications, 14.81%
|
|
|
International Journal of Molecular Sciences
2 publications, 7.41%
|
|
|
Frontiers in Veterinary Science
2 publications, 7.41%
|
|
|
Stem Cell Reviews and Reports
2 publications, 7.41%
|
|
|
World Journal of Stem Cells
1 publication, 3.7%
|
|
|
Animals
1 publication, 3.7%
|
|
|
Molecules
1 publication, 3.7%
|
|
|
Frontiers in Molecular Biosciences
1 publication, 3.7%
|
|
|
Journal of Molecular Medicine
1 publication, 3.7%
|
|
|
Biotechnology Letters
1 publication, 3.7%
|
|
|
Biomedicine and Pharmacotherapy
1 publication, 3.7%
|
|
|
Journal of Functional Foods
1 publication, 3.7%
|
|
|
Journal of Cellular and Molecular Medicine
1 publication, 3.7%
|
|
|
Experimental Dermatology
1 publication, 3.7%
|
|
|
Nucleic Acids Research
1 publication, 3.7%
|
|
|
Oxidative Medicine and Cellular Longevity
1 publication, 3.7%
|
|
|
Biochimica et Biophysica Acta - Molecular Cell Research
1 publication, 3.7%
|
|
|
Biochimica et Biophysica Acta - Reviews on Cancer
1 publication, 3.7%
|
|
|
American Journal of Reproductive Immunology
1 publication, 3.7%
|
|
|
Dental Materials
1 publication, 3.7%
|
|
|
Journal of Molecular Histology
1 publication, 3.7%
|
|
|
1
2
3
4
|
Publishers
|
1
2
3
4
5
6
7
|
|
|
Frontiers Media S.A.
7 publications, 25.93%
|
|
|
Springer Nature
5 publications, 18.52%
|
|
|
Elsevier
5 publications, 18.52%
|
|
|
MDPI
4 publications, 14.81%
|
|
|
Wiley
3 publications, 11.11%
|
|
|
Baishideng Publishing Group
1 publication, 3.7%
|
|
|
Oxford University Press
1 publication, 3.7%
|
|
|
Hindawi Limited
1 publication, 3.7%
|
|
|
1
2
3
4
5
6
7
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.